

Biosecure ID Welcomes Natalie Tyler as Chief Commercial Officer to Lead Mission-Driven Global Forensic Science Solutions

Natalie Tyler joins Biosecure ID as CCO to drive global-local strategy in decentralised DNA testing and expand access to forensic innovation worldwide.

MACCLESFIELD, UNITED KINGDOM, June 16, 2025 /EINPresswire.com/ -- BioSecure ID Limited is



Natalie's leadership will help scale forensic DNA innovation in a way that's inclusive, resilient, and impactful—bringing decentralised testing closer to communities worldwide."

Yogesh Prasad, CEO of Biosecure ID

pleased to welcome Natalie Tyler as Chief Commercial Officer (CCO), joining our founding team. Natalie joins us at a pivotal moment in our journey as we expand our efforts to make DNA-based biometrics and forensic testing more accessible, decentralised, and locally empowering, especially in communities that have long lacked access to these critical technologies.

With over 27 years in the Human Identification (HID) field, Natalie brings a wealth of leadership experience from senior roles at the UK Forensic Science Service and QIAGEN'S HID Division. Highly respected across EMEA and

APAC, she has successfully built commercial businesses, led high-impact forensic programmes, and developed lasting partnerships rooted in trust, innovation, and purpose.

She has led global programs, developed sustainable customer partnerships, and driven large-scale, country-level transformation efforts in forensic DNA. Her approach strikes a balance between operational excellence and empathy, integrity, and a forward-thinking mindset.

Forensic Science Solutions: Available Right Now

As part of its global strategy, the company is building decentralised DNA testing capabilities by equipping small and mid-sized labs and enabling local programmes in Tier 2 and Tier 3 cities to increase casework sample processing. This approach reduces turnaround times, lowers costs, and brings justice and safety closer to the communities who need it most. Biosecure ID enhances national DNA programmes through improved workflows—especially for differential extraction and compromised samples—and by integrating open-source validation tools and Al-

driven decision support software to increase efficiency without added operational burden.

<u>A Trusted Partner in Global Forensic</u> <u>Programmes</u>

Biosecure ID operates as a Value Added Reseller (VAR), working in close collaboration with partners such as Innogenomics Technologies LLC, Paragon Genomics Inc., Gentueri Inc., and others to deliver project-based solutions across local, regional, and global programmes.

Key areas of focus include advancing state-of-the-art DNA quantitation and differential extraction technologies from Innogenomics Technologies, and



developing NGS-platform-agnostic, validated panels in partnership with Paragon Genomics Inc., integrated with robust data analysis and validation tools to ensure reliability and scalability in diverse operational environments. In collaboration with Science for Social Good CIC and Gentueri Inc., Biosecure ID plans to develop affordable, high-quality universal sexual assault sample collection kits, specifically designed to meet the needs of Low- and Middle-Income Countries (LMICs).

The company provides professional services across a range of mission-critical initiatives, including offender DNA databases, laboratory setup, validation, and accreditation, as well as missing persons programmes and national biometric strategies—serving applications in public safety, security, and defence.

Driving Innovation, Empowering Communities

Our Research and Development centre is based at Bruntwood Alderley Park, Macclesfield. We have continued to advance next-generation molecular testing platforms and field-based solutions, focusing on contextual crime analysis and the rapid generation of investigative leads for fast-moving criminal investigations, as well as enhancing coordination between Forensic Labs and Law Enforcement Agencies. This represents a significant gap in the current Rapid DNA testing modality, representing a market opportunity of over US\$1.35 billion globally, based on internal estimates.

Biosecure ID plans to raise £2.5 million (approximately US\$3.5m) over the next 18 months

through Enterprise Investment Scheme (EIS) and the Seed Enterprise Investment Scheme (SEIS) backed by HMRC (His Majesty's Revenue and Customs), and other angel funding avenues, targeting life science–focused funding instruments to support its research and development (R&D) programs. This capital will strengthen our R&D capabilities in molecular testing tools development, NGS-based services to train our ML/AI pipelines, and the development of an AI-driven decision support platform, as well as expand our manufacturing capabilities in the North West of England—an area rich in MSc and PhD-level talent across molecular biology, biochemistry, cellular surface chemistry, nanotechnology, microfluidics, and advanced data science, supported by the region's thriving university ecosystem.

Natalie's leadership as a Commercial Leader will be key in advancing Biosecure ID's global-local strategy, ensuring that powerful molecular testing tools are not only innovative but also trusted, inclusive, and embedded in the communities they serve.

We are proud to welcome Natalie Tyler to the Biosecure ID leadership team and look forward to the impact we will create together.

Yogesh Prasad
Biosecure ID Limited
+44 7720 276924
email us here
Visit us on social media:
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/822481465

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.